Rousselot Showcases Nextida® NxCogni™ Collagen Peptides At SupplySide Global 2026

Oct 29, 2026

Leave a message

news-1536-1024

Selected Peptides Define the Ingredient's Composition

Darling Ingredients says Nextida® NxCogni™ contains more than 10 selected peptides at concentrations exceeding 100 times those found in the standard hydrolyzed collagen it used for comparison. The figure describes the concentration of selected peptides in the ingredient. For supplement developers, this makes the peptide profile a central part of raw material evaluation. Technical details such as the identities of the measured peptides, the analytical method, and the reference collagen would help buyers interpret the comparison and understand how the supplier verifies the profile across production lots.

Powder Format Supports Capsule and Tablet Development

Rousselot is offering NxCogni™ as a powder for incorporation into capsules and tablets. The company describes the intended daily amount as low and presents this as a practical advantage for manufacturers working within the space available in each dosage unit. For a capsule, the amount that fits depends partly on the powder's bulk density and how it flows during filling. For a tablet, developers can assess how the blend compresses with other ingredients and excipients. These formulation considerations help determine whether the powder fits a proposed supplement design.

news-1536-1024

news-1536-1024

Human Research Is Planned in Two Stages

The company's launch announcement outlined an open-label human study planned for December 2026, followed by two large-scale randomized controlled trials planned for the first quarter of 2027. The announcement described the research available at launch as preclinical. An open-label study can provide initial observations in people, while randomized controlled trials can assess differences between study groups under a defined protocol. Once results become available, the study populations, comparison groups, and measured outcomes will help readers judge how directly the findings apply to the ingredient's proposed cognitive wellness positioning.

Las Vegas Showcase Introduces NxCogni™ to Supplement Developers

Rousselot featured the ingredient at booth 4443 during SupplySide Global, bringing it before an audience of dietary supplement brands, formulators, and manufacturers. The product expands the Nextida® platform, which also includes Nextida® GC, and gives Rousselot a collagen peptide offering positioned for the cognitive wellness category. The trade show marked the ingredient's introduction to formulation teams, while the planned studies set out a separate research timetable. For developers assessing the launch, the immediate questions concern powder handling, fit within a capsule or tablet, and the specifications available for the supplied ingredient.

news-1536-1024

 

Send Inquiry